Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal ®)

To evaluate the immunogenicity and tolerability of Epaxal ® in infants and children, 30 infants (aged 6–7 months) and 30 children (aged 5–7 years) received a single intramuscular dose of the aluminium-free virosomal hepatitis A virus (HAV) vaccine Epaxal ® and a booster dose after 12 months. Anti-HA...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2003-11, Vol.21 (31), p.4588-4592
Main Authors: Usonis, V., Bakasénas, V., Valentelis, R., Katiliene, G., Vidzeniene, D., Herzog, C.
Format: Article
Language:English
Subjects:
Age
Aluminium-free vaccine
Aluminum
Antigens
Biological and medical sciences
Body temperature
Child
Child, Preschool
Confidence intervals
Drug dosages
Epaxal
Female
Fundamental and applied biological sciences. Psychology
Hepatitis
Hepatitis A
Hepatitis A Vaccines - administration & dosage
Hepatitis A Vaccines - immunology
Hepatitis A virus
Hepatitis Antibodies - analysis
Hepatitis Antibodies - biosynthesis
Human viral diseases
Humans
Immunization Schedule
Immunization, Secondary
Immunogenicity
Infant
Infants
Infections
Infectious diseases
Influenza
Male
Medical sciences
Microbiology
Pilot Projects
Preschool children
Studies
Vaccine
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies
Viral diseases
Viral hepatitis
Virology
Virosomes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c450t-17784dfc00704fb54ad62f41b2deef96ee91f440b003cf18be2ec23fe37be22c3
cites cdi_FETCH-LOGICAL-c450t-17784dfc00704fb54ad62f41b2deef96ee91f440b003cf18be2ec23fe37be22c3
container_end_page 4592
container_issue 31
container_start_page 4588
container_title Vaccine
container_volume 21
creator Usonis, V.
Bakasénas, V.
Valentelis, R.
Katiliene, G.
Vidzeniene, D.
Herzog, C.
description To evaluate the immunogenicity and tolerability of Epaxal ® in infants and children, 30 infants (aged 6–7 months) and 30 children (aged 5–7 years) received a single intramuscular dose of the aluminium-free virosomal hepatitis A virus (HAV) vaccine Epaxal ® and a booster dose after 12 months. Anti-HAV antibody titres were measured at baseline (before injection), at 1 and 12 months after primary vaccination, and 1 month after the booster vaccination. Sixteen evaluable infants had maternal anti-HAV antibodies at baseline. Complete seroprotection (titre ≥20 mIU/ml) was achieved by all infants and children at Month 1 and at Month 12. Additionally, all subjects showed a strong antibody response to booster vaccination. In infants without maternal anti-HAV antibodies, the response was four-fold higher than in those with maternal anti-HAV antibodies. Both doses of Epaxal ® were well tolerated. These preliminary data suggest that Epaxal ® is an effective hepatitis A vaccine for children and infants from 6 months of age.
doi_str_mv 10.1016/S0264-410X(03)00509-7
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71299003</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X03005097</els_id><sourcerecordid>71299003</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-17784dfc00704fb54ad62f41b2deef96ee91f440b003cf18be2ec23fe37be22c3</originalsourceid><addsrcrecordid>eNqF0d1uFCEUB3BiNHatPoKGxGjai1FgYJi5MpumfiRNvFAT7wjDHFyaWViBWd17n8eH6JOV3Z3YxJteQeB3TuD8EXpOyRtKaPP2C2ENrzgl389IfU6IIF0lH6AFbWVdMUHbh2jxj5ygJyldk6Jq2j1GJ5QLKaSkC_Rn6bPrw7DD2eUICWubIeJNdGsdd1j7AfchpP3ZVhvjvM4ueBwsdt5qn9OB7MLkf2CzcuMQweNfLq-wxlsXQwprPeIVbEpddgkv5zaAzy43-ne5u_l7_hQ9snpM8GxeT9G395dfLz5WV58_fLpYXlWGC5IrKmXLB2sIkYTbXnA9NMxy2rMBwHYNQEct56QnpDaWtj0wMKy2UMuyZaY-Ra-PfTcx_JwgZbV2ycA4ag9hSkpS1nWl-F5I2040tNnDl__B6zBFXz6hqOCNlILQtihxVKYMJEWwap6vokTt01SHNNU-KkVqdUhTyVL3Yu4-9WsY7qrm-Ap4NQOdjB5t1N64dOcEk0xKXty7o4My3a2DqJJx4A0MLoLJagjunqfcAokXvek</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1546775018</pqid></control><display><type>article</type><title>Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal ®)</title><source>ScienceDirect Journals</source><creator>Usonis, V. ; Bakasénas, V. ; Valentelis, R. ; Katiliene, G. ; Vidzeniene, D. ; Herzog, C.</creator><creatorcontrib>Usonis, V. ; Bakasénas, V. ; Valentelis, R. ; Katiliene, G. ; Vidzeniene, D. ; Herzog, C.</creatorcontrib><description>To evaluate the immunogenicity and tolerability of Epaxal ® in infants and children, 30 infants (aged 6–7 months) and 30 children (aged 5–7 years) received a single intramuscular dose of the aluminium-free virosomal hepatitis A virus (HAV) vaccine Epaxal ® and a booster dose after 12 months. Anti-HAV antibody titres were measured at baseline (before injection), at 1 and 12 months after primary vaccination, and 1 month after the booster vaccination. Sixteen evaluable infants had maternal anti-HAV antibodies at baseline. Complete seroprotection (titre ≥20 mIU/ml) was achieved by all infants and children at Month 1 and at Month 12. Additionally, all subjects showed a strong antibody response to booster vaccination. In infants without maternal anti-HAV antibodies, the response was four-fold higher than in those with maternal anti-HAV antibodies. Both doses of Epaxal ® were well tolerated. These preliminary data suggest that Epaxal ® is an effective hepatitis A vaccine for children and infants from 6 months of age.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/S0264-410X(03)00509-7</identifier><identifier>PMID: 14575771</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Age ; Aluminium-free vaccine ; Aluminum ; Antigens ; Biological and medical sciences ; Body temperature ; Child ; Child, Preschool ; Confidence intervals ; Drug dosages ; Epaxal ; Female ; Fundamental and applied biological sciences. Psychology ; Hepatitis ; Hepatitis A ; Hepatitis A Vaccines - administration &amp; dosage ; Hepatitis A Vaccines - immunology ; Hepatitis A virus ; Hepatitis Antibodies - analysis ; Hepatitis Antibodies - biosynthesis ; Human viral diseases ; Humans ; Immunization Schedule ; Immunization, Secondary ; Immunogenicity ; Infant ; Infants ; Infections ; Infectious diseases ; Influenza ; Male ; Medical sciences ; Microbiology ; Pilot Projects ; Preschool children ; Studies ; Vaccine ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies ; Viral diseases ; Viral hepatitis ; Virology ; Virosomes</subject><ispartof>Vaccine, 2003-11, Vol.21 (31), p.4588-4592</ispartof><rights>2003 Elsevier Science Ltd</rights><rights>2004 INIST-CNRS</rights><rights>Copyright Elsevier Limited Nov 7, 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-17784dfc00704fb54ad62f41b2deef96ee91f440b003cf18be2ec23fe37be22c3</citedby><cites>FETCH-LOGICAL-c450t-17784dfc00704fb54ad62f41b2deef96ee91f440b003cf18be2ec23fe37be22c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15272774$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14575771$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Usonis, V.</creatorcontrib><creatorcontrib>Bakasénas, V.</creatorcontrib><creatorcontrib>Valentelis, R.</creatorcontrib><creatorcontrib>Katiliene, G.</creatorcontrib><creatorcontrib>Vidzeniene, D.</creatorcontrib><creatorcontrib>Herzog, C.</creatorcontrib><title>Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal ®)</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>To evaluate the immunogenicity and tolerability of Epaxal ® in infants and children, 30 infants (aged 6–7 months) and 30 children (aged 5–7 years) received a single intramuscular dose of the aluminium-free virosomal hepatitis A virus (HAV) vaccine Epaxal ® and a booster dose after 12 months. Anti-HAV antibody titres were measured at baseline (before injection), at 1 and 12 months after primary vaccination, and 1 month after the booster vaccination. Sixteen evaluable infants had maternal anti-HAV antibodies at baseline. Complete seroprotection (titre ≥20 mIU/ml) was achieved by all infants and children at Month 1 and at Month 12. Additionally, all subjects showed a strong antibody response to booster vaccination. In infants without maternal anti-HAV antibodies, the response was four-fold higher than in those with maternal anti-HAV antibodies. Both doses of Epaxal ® were well tolerated. These preliminary data suggest that Epaxal ® is an effective hepatitis A vaccine for children and infants from 6 months of age.</description><subject>Age</subject><subject>Aluminium-free vaccine</subject><subject>Aluminum</subject><subject>Antigens</subject><subject>Biological and medical sciences</subject><subject>Body temperature</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Confidence intervals</subject><subject>Drug dosages</subject><subject>Epaxal</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Hepatitis</subject><subject>Hepatitis A</subject><subject>Hepatitis A Vaccines - administration &amp; dosage</subject><subject>Hepatitis A Vaccines - immunology</subject><subject>Hepatitis A virus</subject><subject>Hepatitis Antibodies - analysis</subject><subject>Hepatitis Antibodies - biosynthesis</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunization Schedule</subject><subject>Immunization, Secondary</subject><subject>Immunogenicity</subject><subject>Infant</subject><subject>Infants</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Influenza</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microbiology</subject><subject>Pilot Projects</subject><subject>Preschool children</subject><subject>Studies</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><subject>Virology</subject><subject>Virosomes</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNqF0d1uFCEUB3BiNHatPoKGxGjai1FgYJi5MpumfiRNvFAT7wjDHFyaWViBWd17n8eH6JOV3Z3YxJteQeB3TuD8EXpOyRtKaPP2C2ENrzgl389IfU6IIF0lH6AFbWVdMUHbh2jxj5ygJyldk6Jq2j1GJ5QLKaSkC_Rn6bPrw7DD2eUICWubIeJNdGsdd1j7AfchpP3ZVhvjvM4ueBwsdt5qn9OB7MLkf2CzcuMQweNfLq-wxlsXQwprPeIVbEpddgkv5zaAzy43-ne5u_l7_hQ9snpM8GxeT9G395dfLz5WV58_fLpYXlWGC5IrKmXLB2sIkYTbXnA9NMxy2rMBwHYNQEct56QnpDaWtj0wMKy2UMuyZaY-Ra-PfTcx_JwgZbV2ycA4ag9hSkpS1nWl-F5I2040tNnDl__B6zBFXz6hqOCNlILQtihxVKYMJEWwap6vokTt01SHNNU-KkVqdUhTyVL3Yu4-9WsY7qrm-Ap4NQOdjB5t1N64dOcEk0xKXty7o4My3a2DqJJx4A0MLoLJagjunqfcAokXvek</recordid><startdate>20031107</startdate><enddate>20031107</enddate><creator>Usonis, V.</creator><creator>Bakasénas, V.</creator><creator>Valentelis, R.</creator><creator>Katiliene, G.</creator><creator>Vidzeniene, D.</creator><creator>Herzog, C.</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20031107</creationdate><title>Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal ®)</title><author>Usonis, V. ; Bakasénas, V. ; Valentelis, R. ; Katiliene, G. ; Vidzeniene, D. ; Herzog, C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-17784dfc00704fb54ad62f41b2deef96ee91f440b003cf18be2ec23fe37be22c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Age</topic><topic>Aluminium-free vaccine</topic><topic>Aluminum</topic><topic>Antigens</topic><topic>Biological and medical sciences</topic><topic>Body temperature</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Confidence intervals</topic><topic>Drug dosages</topic><topic>Epaxal</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Hepatitis</topic><topic>Hepatitis A</topic><topic>Hepatitis A Vaccines - administration &amp; dosage</topic><topic>Hepatitis A Vaccines - immunology</topic><topic>Hepatitis A virus</topic><topic>Hepatitis Antibodies - analysis</topic><topic>Hepatitis Antibodies - biosynthesis</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunization Schedule</topic><topic>Immunization, Secondary</topic><topic>Immunogenicity</topic><topic>Infant</topic><topic>Infants</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Influenza</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microbiology</topic><topic>Pilot Projects</topic><topic>Preschool children</topic><topic>Studies</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><topic>Virology</topic><topic>Virosomes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Usonis, V.</creatorcontrib><creatorcontrib>Bakasénas, V.</creatorcontrib><creatorcontrib>Valentelis, R.</creatorcontrib><creatorcontrib>Katiliene, G.</creatorcontrib><creatorcontrib>Vidzeniene, D.</creatorcontrib><creatorcontrib>Herzog, C.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>PML(ProQuest Medical Library)</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Usonis, V.</au><au>Bakasénas, V.</au><au>Valentelis, R.</au><au>Katiliene, G.</au><au>Vidzeniene, D.</au><au>Herzog, C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal ®)</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2003-11-07</date><risdate>2003</risdate><volume>21</volume><issue>31</issue><spage>4588</spage><epage>4592</epage><pages>4588-4592</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>To evaluate the immunogenicity and tolerability of Epaxal ® in infants and children, 30 infants (aged 6–7 months) and 30 children (aged 5–7 years) received a single intramuscular dose of the aluminium-free virosomal hepatitis A virus (HAV) vaccine Epaxal ® and a booster dose after 12 months. Anti-HAV antibody titres were measured at baseline (before injection), at 1 and 12 months after primary vaccination, and 1 month after the booster vaccination. Sixteen evaluable infants had maternal anti-HAV antibodies at baseline. Complete seroprotection (titre ≥20 mIU/ml) was achieved by all infants and children at Month 1 and at Month 12. Additionally, all subjects showed a strong antibody response to booster vaccination. In infants without maternal anti-HAV antibodies, the response was four-fold higher than in those with maternal anti-HAV antibodies. Both doses of Epaxal ® were well tolerated. These preliminary data suggest that Epaxal ® is an effective hepatitis A vaccine for children and infants from 6 months of age.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>14575771</pmid><doi>10.1016/S0264-410X(03)00509-7</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0264-410X
ispartof Vaccine, 2003-11, Vol.21 (31), p.4588-4592
issn 0264-410X
1873-2518
language eng
recordid cdi_proquest_miscellaneous_71299003
source ScienceDirect Journals
subjects Age
Aluminium-free vaccine
Aluminum
Antigens
Biological and medical sciences
Body temperature
Child
Child, Preschool
Confidence intervals
Drug dosages
Epaxal
Female
Fundamental and applied biological sciences. Psychology
Hepatitis
Hepatitis A
Hepatitis A Vaccines - administration & dosage
Hepatitis A Vaccines - immunology
Hepatitis A virus
Hepatitis Antibodies - analysis
Hepatitis Antibodies - biosynthesis
Human viral diseases
Humans
Immunization Schedule
Immunization, Secondary
Immunogenicity
Infant
Infants
Infections
Infectious diseases
Influenza
Male
Medical sciences
Microbiology
Pilot Projects
Preschool children
Studies
Vaccine
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies
Viral diseases
Viral hepatitis
Virology
Virosomes
title Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal ®)
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T19%3A10%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibody%20titres%20after%20primary%20and%20booster%20vaccination%20of%20infants%20and%20young%20children%20with%20a%20virosomal%20hepatitis%20A%20vaccine%20(Epaxal%20%C2%AE)&rft.jtitle=Vaccine&rft.au=Usonis,%20V.&rft.date=2003-11-07&rft.volume=21&rft.issue=31&rft.spage=4588&rft.epage=4592&rft.pages=4588-4592&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/S0264-410X(03)00509-7&rft_dat=%3Cproquest_cross%3E71299003%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c450t-17784dfc00704fb54ad62f41b2deef96ee91f440b003cf18be2ec23fe37be22c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1546775018&rft_id=info:pmid/14575771&rfr_iscdi=true